UAE Von Willebrand Disease Therapeutics Market Report 2023 to 2030

UAE Von Willebrand Disease Therapeutics Market Analysis

$ 3999

UAE Von Willebrand Disease Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Some of the key factors influencing market growth include the introduction of new von Willebrand disease therapies, rising awareness of the condition due to an increase in government initiatives and awareness campaigns, and expanding partnerships and collaborations between top research institutions and regulatory bodies. Major global players in Von Willebrand Disease Therapeutics Market are Octapharma AG Grifols, S.A. Shire plc Bayer AG CSL Behring Pfizer, Inc. Akorn, Inc. Ferring B.V.

ID: IN10AERD068 CATEGORY: Rare Diseases GEOGRAPHY: UAE AUTHOR: Nipun Arora

Buy Now

UAE Von Willebrand Disease Therapeutics Market Analysis Summary

UAE Von Willebrand Disease Therapeutics Market is valued at around $2.81 Mn in 2022 and is projected to reach $4.75 Mn by 2030, exhibiting a CAGR of 6.76% during the forecast period 2023-2030.

Both men and women can be affected by Von Willebrand disease (VWD), although women are more likely to experience problems since it may have an impact on their quality of life and ability to have children. Up to 1% of American women may have VWD, and many don't even realise they do, according to recent data. Women with VWD may struggle with menorrhagia, excessive menstrual bleeding, and bleeding after birth. Their general health may be impacted by these problems. To better understand bleeding disorders that affect women and girls, such as VWD, the CDC undertakes research in collaboration with both public and private organizations. A recent study suggests that many episodes of extremely heavy menstrual bleeding may be caused by von Willebrand disease, the most common kind of underlying bleeding disorder (VWD). In a 2002 CDC study, just 4% of Georgian obstetricians and gynaecologists who took part stated they would have considered VWD as a potential cause of severe menstrual bleeding.

Some of the key factors influencing market growth include the introduction of new von Willebrand disease therapies, rising awareness of the condition due to an increase in government initiatives and awareness campaigns, and expanding partnerships and collaborations between top research institutions and regulatory bodies. Major global players in Von Willebrand Disease Therapeutics Market are Octapharma AG Grifols, S.A. Shire plc Bayer AG CSL Behring Pfizer, Inc. Akorn, Inc. Ferring B.V.

Market Dynamics

Market Drivers

One of the main factors propelling the market's expansion is the increased incidence of Von Willebrand disease (factor VIII deficiency). An important aspect of the Von Willebrand disease (factor VIII deficiency) market's growth rate is the rising healthcare costs that help to improve its infrastructure. The market for Von Willebrand disease (factor VIII deficiency) will grow as long as commercial and governmental organisations continue to step up their efforts to increase public awareness of this disorder. Market expansion will be aided by both high disposable income and a rise in the introduction of novel treatments. The ageing population and a constantly evolving way of life will both speed up market expansion.

Market Developments

On May 31, 2023, Pfizer announced positive results from their global phase 3 BASIS clinical study of marstacimab, the company’s investigational subcutaneous therapy that targets an anticoagulant protein known as tissue factor pathway inhibitor (TFPI) which can be used in Von Willebrand Disease.

Key players

Shire Novo Nordisk Pfizer CSL Behring Baxter International Octapharma Kedrion LFB Biotechnologies Biotest Grifols

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For UAE Von Willebrand Disease Therapeutics Market

By Treatment Type

Desmopressin
Replacement Therapies
Clot-stabilizing Medications
Other Treatment Types

By Route of Administration

Oral
Injection
Other Routes of Administration

By Type

Type 1 von Willebrand Disease
Type 2 von Willebrand Disease
Type 3 von Willebrand Disease

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.